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Abstract
Background
A large number of observational studies have reported harmful effects of low 25-hydroxyvi-
tamin D (25OHD) levels on non-skeletal outcomes. We performed a systematic quantitative
review on characteristics of randomized clinical trials (RCTs) included in meta-analyses
(MAs) on non-skeletal effects of vitamin D supplementation.
Methods and findings
We identified systematic reviews (SR) reporting summary data in terms of MAs of RCTs on
selected non-skeletal outcomes. For each outcome, we summarized the results from avail-
able SRs and scrutinized included RCTs for a number of predefined characteristics. We
identified 54 SRs including data from 210 RCTs. Most MAs as well as the individual RCTs
reported null-findings on risk of cardiovascular diseases, type 2 diabetes, weight-loss, and
malignant diseases. Beneficial effects of vitamin D supplementation was reported in 1 of 4
MAs on depression, 2 of 9 MAs on blood pressure, 3 of 7 MAs on respiratory tract infections,
and 8 of 12 MAs on mortality. Most RCTs have primarily been performed to determine skele-
tal outcomes, whereas non-skeletal effects have been assessed as secondary outcomes.
Only one-third of the RCTs had low level of 25OHD as a criterion for inclusion and a mean
baseline 25OHD level below 50 nmol/L was only present in less than half of the analyses.
PLOS ONE | https://doi.org/10.1371/journal.pone.0180512 July 7, 2017 1 / 39
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Rejnmark L, Bislev LS, Cashman KD,
Eirı´ksdottir G, Gaksch M, Gru¨bler M, et al. (2017)
Non-skeletal health effects of vitamin D
supplementation: A systematic review on findings
from meta-analyses summarizing trial data. PLoS
ONE 12(7): e0180512. https://doi.org/10.1371/
journal.pone.0180512
Editor: Andrzej T Slominski, University of Alabama
at Birmingham, UNITED STATES
Received: May 14, 2017
Accepted: June 18, 2017
Published: July 7, 2017
Copyright: © 2017 Rejnmark et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: This project has received funding from
the European Community’s Seventh Framework
Programme (FP7/2007-2013) under grant
agreement 613977 for the ODIN Integrated Project
[Food-based solutions for optimal vitamin D
nutrition and health through the life cycle, http://
www.odin-vitd.eu/].
Conclusions
Published RCTs have mostly been performed in populations without low 25OHD levels. The
fact that most MAs on results from RCTs did not show a beneficial effect does not disprove
the hypothesis suggested by observational findings on adverse health outcomes of low
25OHD levels.
Introduction
In recent years the number of studies exploring effects of vitamin D beyond its well-known
effects on the musculo-skeletal system have increased markedly. The vitamin D receptor
(VDR) and the enzyme (the 1α-hydroxylase) needed to hydroxylate 25-hydroxyvitamin D
(25OHD) to its active form 1,25-dihydroxyvitamin D (1,25(OH)2D) has been identified in a
large number of different cells. This widespread expression of the 1α-hydroxylase suggests that
local production and action of 1,25(OH)2D to regulate VDR-directed gene expression may be
of importance to the function of many tissues [1]. Moreover, gene array studies have shown
that vitamin D may be involved in the regulation of as much as 5% of the human genome
[1–3].
Studies in different populations from around the world have shown a high prevalence of
vitamin D insufficiency, and observational studies have described associations between low
circulating levels of 25OHD and a large number of diseases, including cardiovascular diseases
(CVD), malignancies, diabetes, obesity, infections, neuropsychiatric, and autoimmune dis-
eases [4–16].
As causality should not be infered from observational studies, there is a strong need for clin-
ical and population based trials. So far, only relatively few randomized clinical trials (RCT),
specifically designed to assess effects of vitamin D on non-skeletal outcomes, have been per-
formed. Nevertheless, the number of papers published on potential causal effects of vitamin D
supplementation is rapidly growing as findings from previously published RCTs, originally
designed to evaluate skeletal effects, are being reanalysed in order to elucidate possible non-
skeletal outcomes. In evidence-based medicine, results from systematic reviews (SR) of RCTs
are considered as the highest level of evidence [17]. Within the last few years, an increasingly
number of SRs has been published, including meta-analyses (MAs) with summary data on
results from RCT on non-skeletal outcomes in response to supplementation with vitamin D
[18–20]. In this paper, our aim is to provide a comprehensive umbrella review on SRs report-
ing MAs with summary results on clinically relevant non-skeletal outcomes from trials on vita-
min D supplementation. In addition, we report characteristics of the individual trials included
in MAs, in order to review the evidence-base providing data for published MAs.
Methods
The present paper is a part of a collaborative study between a number of European research
institutions within a project on food-based solutions for eradication of vitamin D deficiency and
health promotion throughout the life cycle (ODIN project, www.odin-vitd.eu) funded by the
European Commission as part of the Seventh Framework Programme of the European Com-
munity for Research, Technological Development and Demonstration Activities.
At a consensus meeting in Tromsø, Norway, we decided which outcomes to study. Criteria
for selecting studied outcomes were:
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1. Non-skeletal effects of supplementation with vitamin D in terms of either vitamin D2 (ergo-
calciferol) or vitamin D3 (cholecalciferol) have been investigated in at least two randomized
trials.
2. At least one MA published in which findings fromRCTs has been summarized.
3. Outcomes should cover different organ systems and be of clinical importance to European
citizens i.e., outcomes on biomarkers were not considered.
4. Reviews should be published in English
Based on these criteria, we selected to study effects of vitamin D supplementation in trials
on CVD, blood pressure, type 2 diabetes (T2D), body weight, birth weight, malignant diseases,
respiratory tract infections (excluding tuberculosis), depression, and mortality.
We searched PubMed, Embase, and the Cochrane Library until December 1st, 2016 for SRs
published in English within the last 10 years on findings from RCTs testing effects of vitamin
D supplementations on the selected outcomes. The search strings used are detailed in the sup-
plementary file (S1 File).
In addition, we manually searched references cited in the papers as well as papers citing the
selected papers for additional articles. We only included SRs reporting summary data in terms
of MAs. Only MAs on effects of treatment with calciferol (vitamin D2 or D3) were considered.
However, we also accepted MAs including RCTs on activated vitamin D analogues in their
summary estimate, as long as the majority (>50%) of included studies were on calciferol. In
addition, we included a trial on effects of vitamin D supplementation on birth weight although
published outside the predefined time range as this SR reports important information on
potential bias in a previously published trial [21]. While writing the paper, a large MA on
effects of vitamin D supplementation on risk of respiratory infections was published in Febru-
ary 2017 [22]. Although being published after the end of the time period defined a priori, we
decided to include this paper, as it is the largest MA published so far on vitamin D and infec-
tions. A flow chart showing the search profile is shown in Fig 1.
For each MA we assessed its quality using the AMSTAR tool for which the quality is mea-
sured on a scale between 0 to 11 [23]. A total score of 9–11 is considered as ‘good’ quality,
whereas a score of 5–8 shows ‘moderate’ quality and a score of 0–4 indicates a ‘poor’ quality
[24]. Furthermore, for each MA we scrutinize the original papers included in the summary
estimate on studied outcomes. Specific characteristics of the individual trials were systemati-
cally identified, including the population studied and whether (if relevant) subjects were
diagnosed with the disease in question. We also collected information on type of vitamin D
studied, dosing frequency, duration of the intervention, and whether calcium was co-adminis-
tered. Furthermore, we noted whether only participants with low 25OHD levels were included
(defined as 25OHD< 50 nmol/L). Finally, we retrieved information on baseline 25OHD levels
and whether the intervention resulted in a more than 50% increase in 25OHD levels, as well as
the main finding (conclusion) of the trial. We did not perform new MAs, but summarized the
characteristics in tables in order to allow for a quantitative evaluation of characteristics of the
studies forming the evidence base for published MAs.
Results
We identified 54 SRs reporting summary data in terms of a formal MA on effects of vitamin D
supplementation on selected outcomes (Table 1). Included SRs had a mean AMSTAR score of
8.8 (range 6–11) suggesting an overall moderate to good quality. Within each group of studied
non-skeletal health outcomes, mean AMSTAR score varied between 8.4 to 9.8 (Table 1). For
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each outcome, number of RCTs included in one or more of the MAs varied from four to 69 tri-
als. A total of 210 RCTs were included in the MAs.
Cardiovascular diseases (CVDs)
A number of observational studies have reported an inverse association between 25OHD con-
centrations and risk of CVDs [25–27], including a greater carotid intima–medial thickness
Fig 1. PRISMA flow diagram.
https://doi.org/10.1371/journal.pone.0180512.g001
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Table 1. Summary characteristics of meta-analyses and the individual RCTs included in MA on non-skeletal effects of vitamin D supplementation.
CVD BP T2D Body Weight Birth Weight Cancer RTI Dep. Death ALL
Number of meta-analyses 7 9 1 3 6 5 7 4 12 54
Results (main finding)
Beneficial response 0 2 0 0 2 0 3 1 8 16
Harmful 0 1 0 0 1a) 0 0 0 0 2
Null finding 7 6 1 3 3 5 4 3 4 36
AMSTAR Score, mean 8.4 8.9 9 8.3 9.8 9.2 9.8 8.5 9.2 8.8
Number randomized clinical trials 21 59 4 32 14 19 30 12 59 210b
Results (main finding)
Beneficial response 0 8 0 2 4 1 9 3 0 27
Harmful 0 0 0 1 0 0 1 0 2 4
Null finding 21 51 4 29 10 18 20 9 57 219
Disease studied was primary outcome?
Yes 0 15 1 5 5 0 23 4 0 53
No 21 44 3 27 9 19 7 7 59 196
Not reported 0 0 0 0 0 0 0 1 0 1
Gender
Only women 13 12 1 14 14 11 2 4 26 97
Only men 0 1 0 2 0 1 1 0 1 6
Men and women 8 46 3 16 0 7 27 8 32 147
Number of included participants
<1000 15 58 2 31 14 13 28 9 43 213
 1000 6 1 2 1 0 6 2 3 16 37
Characteristics of participants
Diagnosed with the disease studied 1 7 1 11 NA 0 11 3 NA 34
Not diagnosed with the disease 20 52 3 21 NA 19 19 9 NA 143
Vitamin D supplements used:
Vitamin D3 13 56 4 29 9 15 30 11 43 86
Vitamin D2 2 3 0 2 4 1 0 0 12 17
Calciferol (D2/D3) b) 1 0 0 0 1 0 0 0 3 5
Activated vitamin D 5 0 0 1 0 3 0 1 1 13
Frequency of vitamin D administration
Single dose 0 6 0 0 3 0 1 1 2 13
Daily 17 29 3 23 4 14 16 7 39 152
Less than daily 4 24 1 9 7 5 13 4 18 85
Co-administration of calcium
No 9 47 1 18 10 11 29 8 27 160
Only to the vitamin D group 5 4 2 5 2 5 0 2 24 49
Both vitamin D and control group 7 8 1 9 2 3 1 2 8 41
25OHD < 50 nmol/L as inclusion criteria
No 19 8 4 26 14 18 29 11 54 183
Yes 2 51 0 6 0 1 1 1 5 67
Mean 25OHD levels at baseline
< 50 nmol/L 7 37 1 15 5 8 7 5 27 112
 50 nmol/L 6 18 2 11 1 9 13 3 16 79
Not reported 8 4 1 6 8 2 10 4 16 59
Duration of follow-up
< 1 year 1 50 1 16 NA 4 18 8 19 117
 1 year 20 9 3 16 NA 15 12 4 40 119
Mean changes in P-25OHD levels compared with
baseline:
< 50% increase 4 15 2 15 2 8 10 3 23 82
 50% increase 6 37 1 12 4 7 9 5 17 98
Not reported 11 7 1 5 8 4 11 4 19 70
NA: not appropriate; Dep: depression.
a)Strong suspicion that data from one of the studies included in the MA were wrongly stated in the published paper (see text in section on birth weight)
b)Some RCTs were included in more than one MA, why total number of RCT within the row do not sum up to N = 210
https://doi.org/10.1371/journal.pone.0180512.t001
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[28], peripheral arterial disease [29], and risks of cardiovascular (CV) death [30,31]. Moreover,
MAs on data from observational studies have consistently found an increased risk of CVD in
subjects with vitamin D insufficiency [32,33]. An effect of vitamin D on CV health is further-
more biologically plausible, as the 25OHD-1α-hydroxylase enzyme is expressed by CV tissues
and the VDRs have been identified in vascular smooth muscle cells, cardiomyocytes, as well as
in coronary arteries [34–36]. Given the presence of the VDR in the vascular system, vitamin D
may potentially improve CV health through several biological pathways. For example, activa-
tion of the VDR has been shown to inhibit vascular smooth muscle cell proliferation, which is
believed to be cardio-protective [37,38]. Moreover, a state of chronic inflammation is consid-
ered to play a key role in the initiation and progression of CVD [39,40], and several studies
have shown an inverse association between 25OHD levels and markers of inflammation, sug-
gesting that vitamin D also may protect against CVD by lowering the state of inflammation
[41–43]. On the other hand, trials assessing the effects of vitamin D supplementation on arte-
rial stiffness, a marker of cardiovascular risk, have shown ambiguous results. In a MA includ-
ing data from seven RCTs involving a total of 547 participants, supplementation with vitamin
D3 for 2 to 12 months showed no significant effects on changes in pulse wave velocity [44].
Nor did a MA including data from seven RCTs suggest beneficial effects of vitamin D supple-
mentation on left ventricular function or exercise tolerance [45].
We identified 10 SR among which seven reported summary data for incident CVDs in
terms of formal MAs, whereas three SRs considered the interventions and outcomes in pub-
lished RCTs to be too heterogeneous for MA [36,46,47]. Table Aa in S1 File shows the seven
SRs reporting pooled data on results from RCTs on effects of vitamin D supplementation on
risk of CVDs [48–54]. None of the MAs showed neither beneficial nor harmful effects on esti-
mates in response to the interventions on risk of CVDs, in terms of any CV events, myocardial
infarctions (MI), stroke/ cerebrovascular disease, or CV death (Table Aa in S1 File). In several
of the MAs summary risk estimates were stratified by whether vitamin D was provided alone
or in combination with calcium (CaD), showing no effects of any of the interventions. Only
one of the seven MAs addressed whether supplementation to individuals with low vitamin D
levels may result in beneficial effects on cardiovascular health, showing no significant interac-
tion when comparing risk estimates from studies with mean 25OHD levels below vs. above 50
nmol/L on stroke (Pinteraction [Pi] = 0.36) or myocardial infarction (Pi = 0.83) [49]. Neither did
interaction analyses suggest differences according to whether the intervention resulted in
increased (unspecified) 25OHD levels on risk of stroke (Pi = 0.41) or myocardial infarction
(Pi = 0.34) [49].
Numbers of RCTs included in each MA varied from two to 11 RCTs, and the total number
of randomized participants included in the RCTs varied between 2,988 and 48,647. The seven
MAs included data from a total of 21 RCTs (Table Ab in S1 File), among which 16 were on
effects of treatment with calciferol and five on treatment with activated vitamin D analogues.
Only the study by Trivedi et al. [55] was included in all seven MAs, whereas two trials were
included in six of the MAs.
Summary characteristics of the 21 RCTs are shown in Table 1. None of the trials had pre-
specified CVD as their primary outcome. Most of the trials included only women, and none of
the RCTs studied only men. Six of the RCTs were large-scale studies with more than 1000 par-
ticipants. Only one of the trials included paticipants recruited based on cardiovascular risk fac-
tors in terms of systolic hypertension [56]. Thirteen RCTs investigated effects of vitamin D3,
two studied effects of vitamin D2 and one study did not report specifically whether the inter-
vention was D2 or D3. In five studies, all included (only) in the MA by Ford et al. [53], effects
of activated vitamin D analogues were investigated. In most of the studies, vitamin D was
administered as a daily dose and calcium was co-administered in approximately half of the
Vitamin D and non-skeletal health
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studies. Only two trials had low 25OHD levels (< 50 nmol/L) as inclusion criteria [57,58], in
which 352 participants who received treatment for one-year participated [57,58]. In addition,
four RCTs reported mean 25OHD levels at baseline below 50 nmol/L [56,59–61], in which
approximately 8000 participants were randomized to treatment for one to five years. Among
the 16 trials investigating effects of vitamin D2 or D3, only four reported an increase in
25OHD levels of more than 50% in response to the treatment. None of the included RCTs
reported neither beneficial nor harmful effects on risk of CVDs in response to the interven-
tions. While writing this review, we noticed that findings from a large RCT (one of the so
called ‘mega-RCTs’) were published on effects of vitamin D treatment on risk of CVD in the
general population as primary endpoint. In the study, Scragg et al [62] randomized 5110 par-
ticipants (42% females) to receive placebo (n = 2552) or vitamin D3 (n = 2558) with an initial
dose of 200,000 IU, followed a month later by monthly doses of 100,000 IU, for a median of
3.3 years. The study showed no beneficial effects of vitamin D supplementation on risk of
CVD (hazard ratio [HR] 1.02; 95% confidence interval [CI] 0.87 to 1.20). The study population
had a mean (SD) baseline deseasonalized 25OHD concentration of 66 (26) nmol/L and 25% of
studied subjects had 25OHD levels below 50 nmol/L at baseline. Similar to the main analysis,
sub-analyses on effects of vitamin D supplementation within the group of participants with
25OHD levels below 50nmo/L showed no effects of the intervention.
In summary, a discrepancy seems to exist between findings from observational studies and
randomized trials on effects of vitamin D on risk of CVDs. Nevertheless, none of the RCTs
included in the MAs have been designed to specifically address whether supplementation with
vitamin D affects CV health and available data from secondary analyses are, as reviewed above,
characterized by a high degree of heterogeneity. However, the recently published study by
Scragg et al [62] with CVD as primary outcome does not support beneficial effects of vitamin
D supplementation on risk of CVD. Importantly, whereas observational studies have reported
adverse health effects on CV health of low 25OHD levels, only few of the RCTs published have
specifically investigated effects in a population with low 25OHD levels.
Blood pressure
A possible link between vitamin D and hypertension has been extensively investigated. Strong
observational data associate low 25OHD levels with an increase in blood pressure and an
increased risk of hypertension [63–65]. Moreover, a large Mendelian randomization analysis
concluded that increased 25OHD levels might reduce risk of hypertension [66]. Vitamin D
may control blood pressure through its regulatory effects on the renin–angiotensin–aldoste-
rone system (RAAS) [67,68]. Vitamin D may suppress the renin biosynthesis [67], and human
studies have shown increased levels of renin and angiotensin II in subjects with vitamin D defi-
ciency [69,70]. Moreover, a positive correlation has been shown between PTH and angiotensin
II/ aldosterone [68,71,72]. Trials with vitamin D supplementation have furthermore shown
that vitamin D stimulates various effects on the endothelia, smooth muscle cells, and in macro-
phages. Such local mechanisms of action on the vessel wall have been suggested to be of impor-
tance for blood pressure regulation [73–77].
We identified nine SRs on RCTs reporting effect of vitamin D supplementation on blood
pressure [46,49,78,79] [80–84] (Table Ba in S1 File). A significant reduction in SBP (range
-6.18 mmHg. to -2.44 mmHg) with no effect on DBP was reported in two of the MAs each
including four RCTs with approximately 400 participants [78,79]. In the study by Withham
et al. [78] only participants from studies with elevated mean baseline blood pressure were
included and effects on blood pressure was designated as the primary outcome. In contrast, in
Vitamin D and non-skeletal health
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the MA by Wu et al. [79] studies on patients with hypertension were not considered, but the
majority of included participants had, nevertheless, arterial hypertension.
No beneficial effects of vitamin D supplementation were, however, reported in two recent
MAs by Beveridge et al [81] and Golzarand et al [83], including 38 and 30 RCTs, respectively.
The two MAs included a meta-regression analysis on dose-response effects showing no associ-
ations between daily dose (-equivalent) of vitamin D supplementation and changes in BP. Sim-
ilarly, the MA by Wu et al. (66) showed no dose-response effects. This is in contrast to the
MAs published by Pittas et al. (39) showing a beneficial dose-response effect on DBP. In
response to a daily dose above 1000 IU, DBP was significantly reduced compared with a daily
dose below 1000 IU.
Three MAs have addressed effects of vitamin D in combination with calcium [46,79,83].
Two of the MAs showed no difference in change in SBP and DBP according to whether vita-
min D was tested alone or in combination with calcium D, whereas the MA by Golzarand et al
[83] found a significantly increase in SBP (3.64 mmHg, 95%CI: 3.15–4.13) and DBP (1.71
mmHg, 95%CI: 1.25–2.18) in response to treatment with CaD.
Two MAs have investigated effects of vitamin D supplementation in specific populations.
By pooling results from 15 RCTs on patients with T2D, Lee et al. [84] found no effects of vita-
min D on SBP, although DBP was slightly but significantly (p = 0.02) reduced (SMD –0.160
(95% CI –0.298 to –0.022) mmHg, I2 = 0%). In contrast, an increase in SBP (WMD: 0.237;
95% CI, 0.110 to 0.365) was found in a trial level MAs by Manousopoulou et al. [82], including
five RCTs on adults with obesity.
Only two of the MAs have investigated whether baseline 25OHD levels are of importance.
In the MA by Withham et al. [77], all four studies included reported mean 25OHD level below
50 nmol/L with a summary estimate showing a significantly decreased SBP in response to the
intervention. In contrast, a trial-level meta-regression analyses in the SR by Beveridge et al
[81] showed no significant effects on responses in blood pressure of baseline 25OHD levels or
increases of 25OHD levels in response to supplementation.
The nine MAs included data from 59 RCTs with a total of 42,814 participants. The majority
of the participants were from the WHI study, whereas the number of participants ranged from
16 to 511 in the other 58 RCTs (Table 3B in Bb S1 File). The studies have been published
between 1983 and 2015. Eight of the RCTs had a duration of one-year or more and none of
these studies with long duration showed a reduced BP in response to the intervention.
In 49% of the studies, vitamin D was administered as a daily dose and calcium was co-
administered in 12 of the studies. Most trials used oral vitamin D3, but one study [85] reports
the effect of UVB vs. UVA radiation and in one study the effect of a single dose vitamin D2
was investigated [86]. Although 25OHD levels below 50 nmol/L was only required as an inclu-
sion criteria in eight (14%) of the studies, mean 25OHD levels at baseline were below 50 nmol/
L in 63% of the trials and increased by more than 50% in response to the supplementation in
almost two-third of the trials (Table 1).
Overall, eight RCTs reported a beneficial response of vitamin D on blood pressure [85–92],
whereas 51 studies found no effects (Table Bb in S1 File). Among the eight studies reporting
a beneficial response, two had low 25OHD levels as inclusion criteria [86,87] and six of the tri-
als reported a mean 25OHD level at baseline below 50 nmol/L [85–87]. Furthermore, five of
the studies reported a mean increase in 25OHD levels of 50% or more in response to the inter-
vention [85,87,88,90,92]. Type of vitamin D intervention varied widely between the eight stud-
ies showing beneficial effects. Three studies used vitamin D in combination with calcium
[87,89,91] and one study used UVB exposure [85]. The remaining four studies administrated
vitamin D using different dosing regimens in terms of a daily dose [90], a weekly dose [92], a
single high dose [86], or a 50,000 IU dose of D3 administrated twice three weeks apart [88].
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The populations studied in the eight trials varied widely. Some studies included patients with
mild hypertension, others pregnant women or healthy normotensive persons. In additin, as
recently highlighted in a paper by Veloudi et al. [93], only a small proportion of the trials on
effects of vitamin D supplementation on blood pressure have actually examined effects in
patients with low vitamin D levels. Similarly, we found that only eight of 51 trials (16%)
included in published MAs had a 25OHD level below 50 nmol/L as inclusion criterion.
In summary, two of nine published MA and eight of 59 individual RCTs included in the
MAs, showed beneficial effect of vitamin D supplementation on BP, whereas one MA found
an increase in SBP in obese adults in response to vitamin D supplementation. Overall, these
results do not provide substantial support for the findings from the observational studies on
an importance of vitamin D on blood pressure regulation. Nevertheless, as most trials on
effects of vitamin D supplementation has been performed in populations without low 25OHD
levels, the hypothesis raised by observational studies on adverse effects of low vitamin D levels
has in reality not been tested to a large extent by trials performed so far.
Diabetes
Numerous observational studies have shown lower 25OHD levels in patients with T2D com-
pared with the general population, as well as an inverse association between 25OHD levels and
fasting plasma glucose, impaired glucose tolerance, and HbA1c levels [94–103]. In studies on
potential biological actions of vitamin D in relation to glucose homeostasis, vitamin D has
been suggested to be of importance to insulin secretion and action. The pancreatic islet cells
have been shown to express the VDR as well as the 1α-hydroxylase enzyme, enabling conver-
sion of 25OHD into its active form directly by the β-cells [104,105]. In animal experimental
studies, vitamin D deficiency inhibits pancreatic secretion of insulin [106] and vitamin D
repletion of rats with vitamin D insufficiency has been shown to improve glucose tolerance
and glucose-stimulated insulin release [107,108]. Trials in humans on potential effects of vita-
min D supplementation on indices of glucose homeostasis have, however, not demonstrated a
clear beneficial effect. Recent MAs on results from RCTs showed no significant improvement
on indices of glucose homeostasis including HbA1c levels in those treated with vitamin D
compared with placebo [19,109–111]. Restricting study subjects to patients with diabetes or
impaired glucose tolerance, one of the MA showed, nevertheless, a small but significant
improvement in fasting glucose levels (−0.32 mmol/L, 95% CI, −0.57, −0.07) and a small
improvement in insulin resistance (SMD −0.25, 95% CI, −0.48, −0.03) [109]. As these reviews
provides a comprehensive update on findings from randomized trials on effects of vitamin D
on biochemical indices of glucose homeostasis, we chose to focus on clinical outcomes in
terms of effects of vitamin D supplementation on risk of incident T2D.
We identified three SRs on risk of incident T2D in RCTs on vitamin D supplementation
[12,112,113]. However, only one of the SRs provided a summary risk estimate based on a MA
[12] (Table Ca in S1 File). The MA included data from four RCTs [114–117], and showed no
effects of vitamin D supplementation on risk of incident T2D [12]. Stratification by glucose
levels at baseline showed no effects on risk of progression in participants with normal glucose
levels or in patients with an impaired glucose tolerance at baseline. The SR did not report
findings according to baseline levels of 25OHD or changes in 25OHD levels in response to
supplementation.
Table Cb in S1 File shows characteristics of the four RCTs included in the MA and charac-
teristics of the RCTs are summarized in Table 1. Only one of the four studies had development
of diabetes as a co-primary end-point [117]. This was a small study that included only 109
patients with pre-diabetes [117]. One study included patients diagnosed with pre-diabetes,
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whereas two studies included participants from the general population and one study included
patients with a previous fracture. None of the studies had low 25OHD levels as a prerequisite
for inclusion and mean 25OHD levels at baseline was only below 50 nmol/L in only one of the
trials [116]. None of the individual RCTs showed beneficial effects of vitamin D supplementa-
tion on risk of incident T2D.
In summary, there is a discrepancy between findings from observational studies and RCTs
on effects of vitamin D on risk of T2D. The number of trials is relatively small and the majority
of subjects included in the trials did not have low 25OHD levels. Accordingly, the findings
from observational studies on an increased risk among those with vitamin D insufficiency can-
not be considered as being disproved by data from RCTs.
Body weight/obesity
Obesity has been associated with low levels of 25OHD in a large number of observational stud-
ies [118–121]. This may be attributable to different mechanisms. Following endogenous syn-
thesis or dietary intake, vitamin D is readily stored in adipose tissue [122]. As the body pool
of fat is larger in obese compared with non-obese individuals, vitamin D may be diluted or
sequestered in the larger body pool of fat resulting in lower plasma levels [123]. Moreover, in a
study by Wortsman et al. [124], it was found that following endogenous synthesis; the release
of vitamin D3 from the skin into the circulation is decreased in obesity. It has also been sug-
gested that obese subjects are less exposed to sunlight, leading to lower 25OHD levels. This
may be due to clothing habits and less involvement in outdoor activities (reduced mobility)
resulting in less skin exposure [125]. Finally, a recently published bi-directional Mendelian
randomization analysis of multiple cohorts showed that a higher BMI leads to lower plasma
25OHD levels whereas low 25OHD levels did not appear to lead to a high BMI [126].
In contrast to the above reviewed findings, suggesting that low vitamin D levels are a conse-
quence of obesity, findings from a number of other studies have suggested that low 25OHD
levels may predispose to obesity. The VDR is expressed by adipose tissue and adipose tissue
has the ability to synthesize 1,25(OH)2D [127,128]. Studies have also suggested that vitamin D
may regulate adipose tissue mass, differentiation and metabolism in ways that might contrib-
ute to obesity [129]. Furthermore, secondary hyperparathyroidism is a well-known conse-
quence of vitamin D insufficiency and increased PTH levels promote calcium influx into the
adipocytes. In adipocytes, intracellular calcium may enhance lipogenesis, and PTH excess may
thereby promote weight gain [130,131]. Conflicting results have been reported on the potential
anti-inflammatory effects of vitamin D. Obesity is considered as a state of chronic low-grade
inflammation [132]. Although several in-vitro and animal experimental studies have suggested
anti-inflammatory effects of vitamin D in obesity, results from human intervention studies
have not shown effects on inflammatory cytokines in response to vitamin D supplementation
[133–135].
In our search for SRs reporting effects of vitamin D supplementation on changes in body
weight, we identified four SRs [82,136–138] among which three provided summary data in
terms of a formal MA including data from 32 RCTs (Table Da in S1 File). Overall, the MAs
showed no effects of vitamin D supplementation on changes in body weight, fat mass (FM),
percentage FM (%FM), or lean body mass. Only the MA by Chandler et al. [138] showed a
beneficial effect on weight loss of supplementation with CaD as compared to placebo.
Table Db in S1 File shows characteristics of the 32 RCTs included in the MA and summary
characteristics of the trials are shown in Table 1. The 32 RCTs have been published between
1987 and 2014. One of the trials included in the MA by Chandler et al. [138] reported effects
on treatment with active vitamin D [139], whereas the other 31 trials reported effects of
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treatment with vitamin D2 (2 RCTs) or D3 (29 RCTs). The majority of the individual trials
reported null-findings. Only two trials found beneficial effects of supplementation [139,140].
In the WHI trial, a secondary analysis on weight changes showed that women randomized to
the CaD group had smaller average annual weight gains than women assigned to the placebo
group [140]. In contrast, Maki et al. [141] reported a significantly increased body weight in
response to eight weeks of treatment with a daily multivitamin and mineral supplement con-
taining D3 1,200 IU D3/d compared with the same supplement without D3. Weight loss was a
primary endpoint in five of the trials [142–146] and none of these showed beneficial effects of
vitamin D intervention. Most of the studies assessed effects in both men and women (N = 16
trials). Number of subjects included was less than 1000 in all of the trials except for the WHI
trial [140]. Eleven (34%) of the trials included participants with (signs of) obesity, none of
them showing beneficial effects of supplementation.
Six (19%) of the studies had low 25OHD levels (<50 nmol/L) at baseline as a criterion for
inclusion, but mean 25OHD levels were below 50 nmol/L in almost half of the studies (N = 15)
and 25OHD levels increased by more than 50% in N = 15 (47%) of the trials in response to the
intervention (Table 1). Only one of the MAs have addressed the importance of 25OHD levels,
showing no effects of either 25OHD levels archived in response to supplementation nor
change in 25OHD levels from baseline in meta-regression analyses on obesity measures [137].
In summary, an inverse association between body weight and 25OHD levels is well docu-
mented. While it is generally agreed that obesity results in low 25OHD levels, it is still disputed
whether low 25OHD levels may contribute to weight gain. Although most of the individual
RCTs included in the MAs were relatively small in terms of number of participants and of
short duration, the studies did, nevertheless, investigate effects of vitamin D supplementation
in populations in which mean 25OHD levels were below 50 nmol/L, as well as 25OHD levels
increased by more than 50% in approximately half of the studies. Accordingly, trial data do
not support a beneficial effect of vitamin D supplementation on weight loss.
Birth weight
Vitamin D insufficiency is common in pregnant women [147–149], and a number of studies
have investigated effects of vitamin D status on pregnancy outcomes. Results from three SRs
on findings from observational studies, suggest a reduced birth weight in infants born by
mothers with low 25OHD levels [18,150,151]. In a MA by Aghajafari et al. [150] a significantly
lower birth weight (weighted mean difference −131g; 95% CI, −187g to −75g) was found in
infants born by mothers with 25OHD levels below 37.5 nmol/L during pregnancy. The MA
also showed a significant inverse association between low 25OHD levels and risk of small ges-
tational age (SGA) infants (OR 1.85; 95% CI, 1.52 to 2.26), as well as risk of gestational diabe-
tes, pre-eclampsia, and bacterial vaginosis [150]. Similar findings were reported in a SR by Wei
et al. [151], in which a MA of observational data showed an increased risk of SGA infants (OR
1.52, 95% CI, 1.08 to 2.15) if maternal 25OHD levels were below 50 nmol/L during pregnancy.
Moreover, in an umbrella review of SRs, Theodoratou et al. [18] reported concordant results
from MA of observational studies and randomised trials, suggesting an increased birth weight
with improved vitamin D status.
Several biological mechanisms responsible for potential effects of vitamin D on fetal devel-
opment have been suggested, including an importance of vitamin D on placental development
through effects on human chorionic gonadotropin expression and placental sex steroid synthe-
sis [152]. Moreover, an increased expression of 1α-hydroxylase and VDR in early pregnancy
trophoblast and decidua tissue has been reported, suggesting an importance of vitamin D in
early foetal development [153].
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In our search for SRs on effects of vitamin D supplementation on birth weight, we identified
eight SR [21,113,154–158] among which six [21,154,155,157–159] reported MAs on pooled
data from RCTs on effects of vitamin D supplements on weight of new-born infants (Table Ea
in S1 File). Three of the MAs were Cochrane reviews which have been continuously updated
[21,155,159]. In the first of the published MA, Mahomed et al. [21] found a reduced birth
weight in response to vitamin D supplementation in a daily dose of 1000 IU/d. However, this
was based on data from two studies with a total of only 176 pregnant women. In one of the
studies, the reported SD of mean birth weight was very low (reported to be 70–90g) whereas it
normally is approximately 600 g [160]. It is likely that the standard error was reported instead
of SD and this may have affected the pooled estimate of the MA. Accordingly, the authors of
the MA conclude that too few data were available to draw conclusions on effects of supple-
mentation on birth weight [21]. In the other five MAs, two showed an increased birth weight
in response to vitamin D supplementation [158,159], whereas three reported null findings
[154,155,157] (Table Ea in S1 File). In one of the SR, data were stratified by dose of vitamin D
supplementation [157], showing no effects on birth weight in neither studies using high doses
nor studies using low doses (Table Ea in S1 File).
The six MAs included data from 14 RCTs. Table Eb in S1 File shows characteristics of the
individual trials included in the MAs and characteristics of the individual trials are summa-
rized in Table 1.
Overall, four of the individual trials reported beneficial effects of the supplementation,
whereas 10 RCTs reported null-findings. Birth weight/fetal growth was considered as a (co-)
primary endpoint in three of the four studies reporting beneficial effects of supplementation
[161–163]. The number of pregnant women included in the 14 trials varied from 50 to 350. In
most studies, vitamin D supplementation was initiated in the 3rd trimester, as only a few stud-
ies started the supplementation in the 2nd trimester [163–166].
Supplementation with vitamin D3 was used in most trials (N = 9), and in three of the four
trials showing beneficial effects on birth weight. All four studies showing a beneficial effect
used high dose treatment in the 3rd trimester either as a single high dose or high doses given
2–3 times. All of the four studies were performed as open label trials in non-western contries
(three in India and one in Iran).
None of the studies had vitamin D insufficiency (25OHD< 50 nmol/L) as criteria for inclu-
sion, and eight of the trials did not report 25OHD levels at baseline or changes in response to
supplementation. None of the four studies showing beneficial effects reported changes in
25OHD levels in response to treatment and only one of the four studies reported baseline
25OHD levels. None of the published MAs, reported effects according to baseline 25OHD lev-
els or changes in 25OHD levels.
Only the studies by Brooke et al. [167] and Hollis et al. [164] reported a 50% increase in
25OHD levels in response to treatment. The study by Brooke et al. [167] had, however, a rather
small sample size whereas the study by Hollis et al. [164] had a reasonable sample size and
used a relatively high vitamin D dose although including women who did not have vitamin D
insufficiency (Table Eb in S1 File).
In summary, in contrast to findings from observational studies, results from most RCTs
have not shown beneficial effect of vitamin D supplementation on birth weight. The quality of
the trials showing an increased birth weight in response to supplementation is limited by the
lack of blinding and measurement of 25OHD levels. Accordingly, available data from RCTs on
effects of vitamin D supplementation on birth weight do not clearly support findings from
observational studies. Of notice, the sample size in most trials have been relatively small and in
most of the studies, the intervention has been of short duration and initiated in late pregnancy,
whereas several observational studies showing an inverse association between 25OHD levels
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and birth weight have assessed vitamin D status in early/mid pregnancy [168]. Accordingly,
the hypothesis raised by findings from observational studies on effects of vitamin D status on
birth weight has not been properly tested in RCTs.
Malignant diseases
A potential antineoplastic effect of vitamin D has been suggested by findings from in vitro
studies, as vitamin D may affect several cellular processes, including proliferation, differentia-
tion, angiogenesis, and apoptosis [169,170]. Although an association between vitamin D and
risk of cancer has not been found in all human studies, several observational studies have
reported an inverse association between risk of cancer and a low dietary intake of vitamin D, a
low degree of sun exposure, or low plasma levels of 25OHD [171–173]. Studies on VDR poly-
morphisms (BsmI, TaqI, FokI, and ApaI) [174,175], and MAs on data from observational stud-
ies also support an association between low 25OHD levels and an increased risk of malignant
diseases [176–180] as well as cancer mortality [181].
We identified eight SRs reporting data from RCT on risk of incident malignant diseases in
response to vitamin D supplementation [52,54,113,182–186]. However, a formal MA reporting
summary risk estimates was only performed in five of the SRs [52,54,184–186] (Table Fa in S1
File).
Following the Evidence/Technology Assessment report on health outcomes of vitamin D
and calcium published in 2009 by Chung et al. [182], Chung and colleagues [183] published an
update in 2011 on cancer outcomes. The SR reports data from three RCTs [55,187,188], but no
pooled summary estimates are reported. The SR concludes that the available data do not allow
for any firm conclusions on harm or benefits of vitamin D supplementation for cancer preven-
tion. Moreover, in a SR on non-skeletal effects of vitamin D by Rosen et al [113], commissioned
by The Endocrine Society, data from three RCTs are reviewed. The three studies included are
similar to those reviewed by Chung et al [183]. No formal MA was performed. In accordance
with the conclusion by Chung et al [183], Rosen et al [113] conclude that there is not sufficient
evidence to draw conclusions on whether vitamin D may affect cancer incidence or mortality
from cancer. However, the paper did not consider a prior analysis performed by Bolland et al.
[189] showing an interaction between use of personal CaD supplements and randomization to
CaD vs. placebo in the WHI trial. The analysis showed a significantly decreased risk of breast
cancers and a non-significantly reduced risk of colorectal cancer in women randomized to CaD
supplementation who did not take personal CaD supplements at randomization [189].
In a SR commissioned by the U.S. Preventive Services Task Force (USPSTF), aiming at
updating the evidence on benefits and harms of vitamin and mineral supplementation to pre-
vent cancer, Fortmann et al. [52] and Keum et al. [186] performed MAs on data from four
RCTs on primary prevention of cancers in the general adult population. None of the analyses
showed effects of vitamin D supplementation on risk of incident cancers, and this was not
changed by stratification on whether the supplementation was provided as vitamin D alone or
vitamin D in combination with calcium (Table Fa in S1 File).
Bjelakovic et al [184] published an elaborated Cochrane review including data from 18
RCTs on risk of incident cancers and cancer mortality. In the SR, a number of MAs were per-
formed showing no significant effects of vitamin D supplementation on risk of developing can-
cer. However, based on data from four studies, the MA showed a significantly reduced risk on
cancer mortality (RR 0.88; 95% CI, 0.78, 0.98). Similarly, a reduced risk of death due to malig-
nancies (RR 0.88; 95% CI, 0.79–0.98, p = 0.03, I2 0%) was also been reported in MAs by Zheng
et al. [190] and Keum et al. [186], both pooling findings from three trials [55,188,191] with a
total of 44,260 randomized participants.
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In another SR, Bolland and colleagues [54] identified SRs published since 2009 that summa-
rized data from RCTs on effects of vitamin D supplementation on risk of cancer. Three MAs
were identified including seven RCT [182,183,192]. Bolland et al. [54] performed a new MA,
based on data from the seven RCTs included in theses three SRs. The new MA showed no
effects of vitamin D supplementation, either alone or in combination with calcium, on risk of
incident cancers (Table Fa in S1 File).
In addition, Sperati et al [185] performed a SR focusing specifically on effects of vitamin D
on risk of breast cancer. The authors identified only two studies fulfilling their pre-defined cri-
teria for inclusion of studies (Table Fa in S1 File). The MA showed no beneficial effects of vita-
min D supplementation and neither was vitamin D dosage nor mode of administration found
to affect risk of breast cancer [185].
Table Fb in S1 File shows characteristics of the 19 RCT included in the five MA and Table 1
summarizes characteristics of the individual studies.
None of the RCTs assessed risk of cancer as a primary outcome. The majority of the studies
was performed in women-only (58%) with less than 1000 randomized participants (68%) and
no RCT included in published SRs provides data on effects of vitamin D supplementation in
patients already diagnosed with cancer. Mean levels of 25OHD at baseline were below 50
nmol/L in less than half of the studies and only one study had low 25OHD levels as an inclu-
sion criteria. Only one of the MAs addressed whether vitamin D status at baseline is of impor-
tance to responses, showing no difference in risk of incident cancers between trials with mean
baseline levels below 50 nmol/L (RR 0.99; 95% CI, 0.93–1.05) compared with studies with
mean 25OHD levels above 50 nmol/L (RR 1.12; 95% CI, 0.94, 1.34) [184].
The majority of studies investigated effects of vitamin D3 administered as a daily supple-
ment. The MA by Bjelakovic et al [184], also included data from three studies on treatment
with activated vitamin D analogues. More than half of the studies investigated effects of vita-
min D alone, whereas calcium was co-administered in seven studies to either only the vitamin
D group (5 RCT) or to both the vitamin D and the control group (3 RCT). Most of the studies
(79%) had a duration of at least one year. The intervention with vitamin D supplementation
increased plasma 25OHD levels by more than 50% in only one-third of the studies. Only one
of the 19 RCTs showed a reduced incidence of cancers in response to supplementation with
vitamin D. This study was performed by Lappe et al [187] and did not have malignant diseases
as a primary outcome (Table Fb in S1 File). Most recently, Lappe et al [193] have published
results from a subsequent double-blind RCT comparing effect of four-years of treatment with
a daily supplement of D3 2000 IU plus 1500 mg of calcium with placebo on risk of incident all-
type cancer (primary endpoint). The trial included 2,303 healthy elderly women with a mean
age of 65±7 years and a mean baseline 25OHD level of 82±26 nmol/L. The study showed no
significant beneficial effects on cancer incidence (HR 0.70; 95% CI, 0.47 to 1.02). However, the
study probably had a too low statistical power to show such an effect [194].
Conclusions: MAs on results from RCTs on effects of vitamin D supplementation on risk of
cancer have concluded that no evidence exists to support a causal relationship. It should, how-
ever, be emphasized that most RCTs included in the SRs have been carried out in groups of
participants without low 25OHD levels and mean changes in 25OHD levels in response to sup-
plementation have either not been assessed or been less than 50% of baseline values in most
studies. In addition, the duration of the intervention has in most studies been rather short.
Interestingly, the WHI study [189] as well as the trials by Lappe et al [187,187] had a relatively
long duration and did suggest beneficial effects. More so, data on specific types on malignant
diseases are largely missing. Accordingly, the evidence-base by which the MAs are grounded
does not seem to be appropriate to reject the findings from observational studies on an
increased risk of cancer in vitamin D insufficiency.
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Respiratory tract infections
For more than a century, vitamin D deficiency has been suggested to increase the susceptibility
to infection. Early observations showed increased risk of respiratory tract infections (RTI) in
children with nutritional rickets and vitamin D was considered of importance in the treatment
of tuberculosis [195,196]. The seasonality of RTIs such as those caused by rhinovirus (“common
cold”) and influenza virus is well known, and low 25OHD levels during wintertime have been
suggested to be the “seasonal stimulus” which increases the susceptibility to such infections [197].
If so, this is of major importance to public health, as RTI are a major contributor to mortality
[198,199]. Recent studies have provided further evidence of vitamin D as an important regulator
of human immune function, as vitamin D may stimulate the innate immune response which
provides front-line protection against infectious agents [200]. The VDR has been shown to be
expressed in different cells of the myeloid and lymphoid lineage and vitamin D may increase the
expression of antimicrobial peptides in human monocytes and neutrophils [201,202]. Particu-
larly, vitamin D may enhance the expression of the human cathelicidin antimicrobial peptide
(hCAP-18) which is of specific importance in host defenses against respiratory tract pathogens
[203]. In accordance with the findings from epidemiological and in-vitro studies, a number of
observational studies have suggested an inverse association between vitamin D status and risk of
infections. Thus, risk of a recent RTI was significantly increased by 24% among participants with
low compared with high 25OHD levels (below/above 75 nmol/L) in the Third National Health
and Nutrition Examination Survey in the USA, which included 18,883 study subjects [204]. Simi-
larly, an inverse association between vitamin D status and risk of developing RTIs has also been
reported in other cohorts as well as a replete vitamin D status has been associated with fewer days
of absence from duty due to RTIs [205–209].
In our search for SRs on effects of vitamin D supplementation on risk of RTIs, we identified
10 SR [22,210–218] among which seven [22,211–213,216–218] reported MAs on pooled data
from RCTs on risk of RTIs in response to vitamin D supplementation (Table Ga in S1 File). In
two trial-level MAs, vitamin D supplementation was found to significantly reduce risk of RTI
by approximately 40% [211,212], which also applied to pediatric populations [211]. The first of
the trial MA found a protective effect by summarizing data from five RCTs [211], the second
trial MA included data from 11 RCTs [212]. A subsequent trial-level MA by Mao et al [213],
however, found no beneficial effects of vitamin D supplementation on risk of RTI. Mao et al
[213] included only data from seven RCTs, as this MA excluded studies which were considered
to be of low quality in terms of a modified Jadad score 3 [219]. Most recently, an individual
patient data analysis (IPD) has been published, including individual data from 10,933 study
subjects included in 25 RCTs [22]. The analysis showed a significantly reduced risk of acute
RTI (OR 0.88, 95% CI, 0.81 to 0.96). Sub-group analyses suggested protective effects in
response to a daily or weekly vitamin D dose (adjusted odds ratio 0.81, 0.72 to 0.91), but not in
response to one or more bolus doses (adjusted OR 0.97, 95% CI, 0.86 to 1.10; Pi = 0.05). More-
over, among those receiving daily or weekly vitamin D, the protective effects were stronger in
those with a baseline 25OHD<25 nmol/L (adjusted OR 0.30, 95% CI, 0.17 to 0.53) than in
those with a baseline 25OHD25 nmol/L (adjusted OR 0.75, 95% CI, 0.60 to 0.95; Pi = 0.006)
[22]. However, two of the other published MAs found no differences between studies with
mean baseline levels above or below 75 nmol/L [212] or 50 nmol/L [218].
The seven MAs included data from a total of 30 RCTs. Table Gb in S1 File shows character-
istics of the individual RCTs included in the seven MAs and characteristics of the individual
trials are summarized in Table 1. None of the MAs included data from all the 30 RCTs.
The majority of studies included both men and women. Only two studies were of a large
scale with more than 1000 participants [220,221] and most studies had a relatively short
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duration. Twenty-three (77%) of the RCTs investigated effects of vitamin D supplementation
as a primary endpoint (Table Gb in S1 File). Eleven trials (37%) included patients diagnosed
with an infection at time of inclusion or at increased risk of acquiring infections. However,
the specific infections studied varied widely between studies e.g., some investigated risk of
pneumonia, upper or lower RTI, or exacerbations in patients with COPD or asthma as well as
some studies included new-borns or infants where other studies focused on adults or elderly
(Table Gb in S1 File). All studies investigated effects of supplementation with vitamin D3 and
half of the trials (53%) administered D3 as a daily dose without concomitant calcium supple-
mentation. Only one of the trials had low 25OHD levels (< 50 nmol/L) as inclusion criteria
and mean 25OHD levels at baseline were only reported in two-thirds of the studies among
which only seven trials reported mean levels below 50 nmol/L. Nine trials (30%) reported a
more than 50% increase in 25OHD levels in response to treatment. A beneficial effect of vita-
min D supplementation on risk of infections was found in nine (30%) of the trials, but none of
the above mentioned indices were in general a characteristic of the trials showing beneficial
effects of the supplementation (Table Gb in S1 File).
In summary, most published studies on effects of vitamin D supplementation on risk of RTI
have been relatively small and of short duration without specifically addressing effects in popu-
lations with vitamin D insufficiency. Beneficial effects of vitamin D supplementation have
been reported in nine of the 30 RCTs included in the 7 published MAs and three of the MAs
have concluded that vitamin D supplementation may lower risk of infections. Noteworthy, the
populations studied in the individual trials have varied widely from newborns to elderly as
well as effects of a wide range of different types of infections have been included raising the
question whether results from such different settings can be merged into MA reporting sum-
mary estimates. Nevertheless, the overall findings suggest a beneficial effect of vitamin D on
respiratory tract infections.
Depression
Vitamin D may affect brain function as the VDR as well as the 1α-hydroxylase enzyme is
expressed by brain tissues, suggesting that 25OHD is activated and functions within the central
nervous system (CNS) [222–224]. This is further supported by findings showing effects of
1,25-OH2D3 on the synthesis of nerve growth factor (NGF) [225,226], as well as the synthesis
of tryptophan is transcriptionally activated by vitamin D and low 25OHD levels may accord-
ingly cause low levels of serotonin [227].
Several cross-sectional- and cohort-studies have reported an inverse association between
plasma 25OHD concentrations and depression [228–234]. In a MA on results from observa-
tional studies, low plasma 25OHD levels were associated with an increased risk of depression
in cross-sectional studies (n = 11 studies with 43,137 participants; OR 0.96; 95% CI, 0.94, 0.99,
I2 = 63%) as well as in cohort studies (n = 5 studies with 12,648 participants; OR 0.92; 95% CI,
0.87, 0.98, I2 = 50%) [235]. Nevertheless, other epidemiological studies have not found such
associations [236–238].
We identified six SRs [239–244] among which four [239–242] provided formal MAs report-
ing pooled data on results from 30 RCTs on effects of vitamin D supplementation on depres-
sion (Table Ha in S1 File).
Performing a systematic literature search, Spedding et al. [239] identified 15 RCTs report-
ing effects of vitamin D supplementation on depression scores including mood disorders such
as (seasonal) recurrent depressive disorder. Studies were subsequently grouped according to the
presence of biological flaws. Biological flaws were considered if baseline 25OHD levels were not
measured, if baseline levels indicated a replete vitamin D status, or if the interventions did not
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cause a significant increase in 25OHD levels. Among the 15 studies identified, eight (53%) were
found to have biological flaws [61,245–251], whereas seven studies (47%) were classified as
being without flaws [252–258]. MAs were performed on studies with or without biological
flaws. In the MA on studies without biological flaws, only two of the seven studies were included
[253,257], as they used the same outcome measure in terms of Beck Depression Inventory
(BDI), whereas other measures were used in the remaining five studies. Among the eight studies
grouped as being with biological flaws, only two were included in MA [61,251] as they both
used the 12-item Short Form Health Survey (SF-12) questionnaire, whereas other measures
were used in the remaining six studies. As shown in Table Ha S1 File, the authors found benefi-
cial effects of vitamin D supplementation in the MA on studies without biological flaws, whereas
no effect was present in the MA on studies classified as being with biological flaws.
In a systematic review by Li et al. [240] studies were only included if vitamin D was pro-
vided orally as mono-intervention and compared with placebo in adults considered to be at
risk of depression, having depressive symptoms, or being diagnosed with depression (second-
ary or tertiary prevention). The protocol for the study was published prior to the results from
the MA [259]. The MA included data from six RCTs (Table Hb in S1 File) among which one
of the studies used calcitriol as treatment [250]. For some of the included studies, only sub-
groups of the randomized population were considered for data-analyses. For example, in the
study by Sanders et al. [61], only 137 of the 2258 randomized women were included, as only
this subgroup provided concurrent information on changes in 25OHD levels and changes in
scores as assessed by the WHI-5 questionnaire. Overall, the meta-analysis by Li et al. [240]
showed no effects of vitamin D supplementation on studied indices (Table Ha in S1 File). In
subgroup analysis stratified by vitamin D dosages, sex, study location, and different study pop-
ulations, no effects of vitamin D were found. In a post hoc analysis stratified by vitamin D sta-
tus at baseline (sufficient vs deficient), no significant differences between groups were
observed [240]. Similarly, Shaffer et al [241] and Gowda et al [242] found no significant differ-
ences when comparing studies with mean baseline 25OHD levels below or above 50 nmol/L.
For most of the analyses performed, a substantial unexplained heterogeneity was present and
the quality of evidence obtained from the included trials was graded as low by the authors
[240]. Similarly, no overall beneficial effects of vitamin D supplementation were found in the
MAs by Shaffer et al (221) and Gowda et al [242] and a substantial and unexplained heteroge-
neity was also found in most analyses (Table Ha in S1 File).
Table Hb in S1 File shows summary characteristics of the 12 RCTs included in the four
MAs. The trials have been published between 2003 and 2013. In four (33%) of the trials,
depression was considered as a primary end-point. Four of the RCTs included only women
(none of the studies included only men). Three studies included solely patients with a diagno-
sis of depression; none of them on treatment with antidepressant at time of inclusion. One
study included only elderly women with known seasonal affective disorders (treatment status
unknown). The remaining studies included community-dwelling men and women among
which two of the studies excluded participants on treatment with antidepressants. In three
studies, participants were only included if they had 25OHD levels below 40 or 55 nmol/L or
between 25–75 nmol/L. In 10 of the studies, vitamin D supplementation was given orally as
vitamin D3 tablets/capsules (9 studies) or as fortified cheese (1 study). One study used intra-
muscular D3-injections and one study tested calcitriol. Vitamin D was given daily (7 studies),
weekly (3 studies), yearly (1 study), or as a single dose (1 study). Time from initiation of treat-
ment to end of follow-up varied from six weeks to five years. Effects were assessed by Beck
Depression Inventory (BDI) in five studies, by the Geriatric Depression Scale (GDS) in two
studies, and by the SF-12 questionnaire in two studies. One study used the Burnam 8-item
scale for depressive disorders whereas another study used a questionnaire designed for patients
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with fibromyalgia which included depression as a domain. Only three of the individual RCTs
showed beneficial effects [254,257,260] among which effects of the intervention was consid-
ered as a primary endpoint in two of the trials [257,260]. In one study, a per-protocol analysis
showed a decrease in depressive symptoms compared with placebo in the cognitive-affective
domain (subscale 1–13) of BDI [253]. In a sub-analysis from the WHI study, the Burnam-
score was worsened by vitamin D compared with placebo (0.009; 95% CI, 0.002, 0.017) in the
group of women without evidence of prior depression [246]. No major effects were shown in
sub-analyses in any of the other studies.
In summary, only one of four MAs has suggested a beneficial effect of vitamin D supple-
mentation on depression. This MA included only few of the published studies, whereas the
three MAs showing no effects of vitamin D supplementation allowed for inclusion of more of
the published RCTs. However, the methods used to assess effects in the various RCTs varied
widely and only few (N = 5) studies reported an increase in 25OHD levels above 50% in
response to the intervention. Moreover, most of the studies (N = 11) did not require their par-
ticipants to have vitamin D insufficiency (25OHD<50 nmol/L) at inclusion and only five stud-
ies reported mean baseline 25OHD levels below 50 nmol/L. It is nevertheless noteworthy that
both the MA by Li et al. [240] and the MA by Shaffer et al [241] suggested beneficial effects of
vitamin D supplementation among those with a replete vitamin D status, but not in subjects
with low vitamin D levels which does not support findings from observational studies of a
major role of vitamin D in the pathogenesis of depression.
Mortality
Observational studies have shown an inverse association between 25OHD levels and mortality,
including death from CVD, cancer, and non-vascular, non-cancer causes [194,261–266]. The
mechanism by which supplementation with vitamin D may reduce mortality has not been
fully clarified, but it has been suggested that the reduced risk of death may be due to the possi-
ble pleiotropic effect that involved the musculo-skeletal- as well as several extraskeletal-sys-
tems, including anti-inflammatory and immune modulating effects [267,268].
We identified 12 SRs with MAs on mortality in response to supplementation with vitamin
D. Eight of the MAs showed a significantly reduced mortality in response to supplementation
(Table Ia in S1 File). In most of the MAs, stratification by type of calciferol showed a signifi-
cantly reduced mortality in response to treatment with vitamin D3, whereas no beneficial
effects were found in response to treatment with vitamin D2 [190,263,269–271]. Discrepant
results have been reported on whether mortality is reduced in response to treatment with vita-
min D alone [263,269] or only if vitamin D is combined with calcium supplements [190,270–
272]. In two MAs, effects of the intervention was significant in summary estimates on trials
with low baseline vitamin D status [190,271], but a clear dose-response relationship has not
been documented [49,269,271,272].
The 12 MAs included data from a total of 59 RCTs. Table Ib in S1 File shows characteristics
of the individual RCTs included in the 12 MAs and characteristics of the individual trials are
summarized in Table 1. None of the RCTs had mortality as a primary endpoint and none of
them showed a significantly reduced mortality in response to treatment. Actually, two small tri-
als showed an increased mortality in response to the supplementation [273,274]. In the study by
Latham et al. [273], a single high dose (300,000 IU) of vitamin D3 increased mortality during
the following six months compared with placebo in a group of 243 frail elderly people. Similarly,
a high dose of D2 (100,000 IU every 3rd month) increased mortality compared with no treat-
ment during a 10 months study period in a group of 3,717 nursing home residents [274]. On
the other hand, none of the studies with daily administration of vitamin D supplements has
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shown increased mortality in response to supplementation, including a recently published trial
on three-years of daily supplementation with 4000 IU D3 or placebo to 400 patients with heart
failure [275]. Most studies have been relatively small with less than 1000 randomized partici-
pants and have investigated effects of a daily dose of vitamin D3 with calcium being co-adminis-
tered in approximately half of the studies. Only few of the studies (N = 5) had low 25OHD
levels as a criterion for inclusion. Seventeen of the 59 studies reported an increase in 25OHD
levels of more than 50% in response to the intervention. Mean 25OHD levels were below 50
nmol/L in approximately half of the studies. Several of the MAs compared effects between stud-
ies with mean baseline levels below or above 50 nmol/L showing no significant interactions
[49,270,276,277]. However, stratified analyses showed a significantly decreased mortality when
pooling results from studies with mean 25OHD levels below 50 nmol/L, but not when combin-
ing results from studies with mean levels above 50 nmol/L [190,270,276].
In summary, supplementation with vitamin D seems to be causally related to a reduce all-
cause mortality, which is in accordance with the findings from observational studies. More-
over, as reviewed in the section on malignant diseases, MAs on cause specific mortality have
shown a reduced mortality due to malignant diseases [184,186,190]. Only vitamin D3 has been
shown to reduce mortality, and some MAs have suggested that the effect only is present if cal-
cium is co-administered, whereas other MAs have shown an effect of vitamin D3 alone. The
lack of a clear dose-response relationship may be attributable to characteristics of the RCTs
included in the MAs, as most of the trials have investigated effects of low doses (Table Ib in
S1 File) which may limit the statistical power to show dose-effect relationships. Furthermore,
as recently shown in a simulation analysis, based on findings from a large cohort study, the
expected impact on mortality of vitamin D supplementation is presumably much higher if tar-
geted to individuals with low 25OHD levels [278].
Discussion
Overall, 16 of the 54 MAs suggested beneficial effects of vitamin D supplementation on differ-
ent extra-skeletal outcomes among which eight of 12 MAs (66%) reported a decreased mortal-
ity. Beneficial effects were also suggested by MAs on blood pressure (2 of 9 [22%] MAs), birth
weight (2 of 6 [33%] MAs), RTIs (3 of 7 [43%] MAs), and depression (1 of 4 [25%] MAs). No
beneficial effects were reported in any of the MAs on CVD, T2D, body weight, or malignant
diseases.
For all studied outcomes, only one-fourth of the individual RCTs included in the MAs had
assessed effects studied as a primary endpoint. None of the trials included in the 12 MAs on
mortality had mortality as a designated primary outcome. Most studies have been performed
only in women or in a mixed gender population, whereas only very few studies included only
men. The sex distribution is probably because many of the included studies have investigated
skeletal effects as primary outcomes. As osteoporosis and fractures are more common in
women than in men, these studies have preferentially included women in order to achieve
effects in a population at high risk. However, although many of the trials have assessed effects
of vitamin D supplementation on skeletal outcomes, only a minority of the studies have actu-
ally investigated effects in populations with low 25OHD levels. Plasma 25OHD levels below 50
nmol/L were only inclusion criteria in one-fourth of the analyses.
Moreover, mean 25OHD levels at baseline below 50 nmol/L has only been measured in less
than half of the studies, indicating that the populations studied did not, on average, suffer from
vitamin D insufficiency and the duration of studies has in many studies been relatively short.
The WHI study is the trial with the longest time of intervention (7 years) and the most partici-
pants included [279].
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The vast majority of observational studies have reported low 25OHD levels to be associated
with an increased risk of adverse health outcomes, but caution is needed in interpreting obser-
vational data. Although most studies have adjusted for differences between groups, residual
confounding can never be excluded in observational studies. Effects may be due to lifestyle fac-
tors, a “healthy user” bias or other differences between groups, which has not been fully
accounted for in adjusted analyses. This may result in reverse causation, in which vitamin D
status is more a marker for an underlying condition/disease than causally related to the disease
investigated. Accordingly, RCTs are needed to determine whether a causal link is present. Fol-
lowing the publications of a large number of observational studies showing adverse health out-
comes of low 25OHD levels, the requests of data from RCTs have increased. For each of the
outcomes we studied, a variable number of RCTs have been published and most of them have
failed to document a beneficial effect as shown in observational studies. Accordingly, it may
seem questionable whether the findings from observational studies actually reflect a beneficial
effect of vitamin D by itself. Due to such findings, a recent large scale review by Autier et al
[19] concluded that the inverse association between 25OHD levels and various health out-
comes, could be the result of disease process causing low 25OHD levels rather than low
25OHD levels causing the disease i.e., low 25OHD levels are a marker of ill health.
In our review, we aimed to summarize characteristics of the published RCTs on effects of
vitamin D supplementation. Although, RCTs are considered as the highest level of evidence,
and especially if results from RCTs are summarized in MA, the degree of confidence on the
findings from the RCTs do, however, depend on how the studies were performed and whether
they actually had a design and statistical power to detect possible effects. Our review highlights
that most of the available trials were not designed to study non-skeletal outcomes of vitamin D
supplementation. For most of the selected outcomes reviewed in this paper, the RCTs included
in MAs did not have the disease in question as primary outcome. For several of the diseases
studied, some of the outcomes were assessed as adverse event reports and many of the studies
had a questionable statistical power to detect effects such as incident CVDs or cancers. The
lack of trials assessing effects of intervention on specific health outcomes as a primary end-
point does, however, not provide a complete answer to the discrepancy between findings from
observational and randomized trials. For example, in analyses on mortality, none of the indi-
vidual RCTs showed beneficial effects and none of the trials were designed to assess mortality.
However, several of the pooled risk estimates in MAs did show a significantly reduced risk of
death in response to treatment. Notably, the MAs on mortality have included substantially
more studies than most of the MAs on other studied outcomes and mortality may be assessed
in a more valid manner than other “adverse effects” observed during a trial. If vitamin D sup-
plementation affects studied outcomes the sample size may have been too small to show effects,
which may have been further hampered by a relatively short duration of treatment. CVD, obe-
sity, T2D, and cancers develop over a long time, and the duration of the trials available may
not be sufficiently long to affect such disease processes. Historically, it has been shown multiple
times that RCTs are difficult to perform in terms of testing the right dose for an appropriate
time-period in a suitable population of study subjects and that null-finings do not necessary
disprove important effects [17,280,281]. Interestingly, a beneficial effect of vitamin D supple-
mentation was shown in several of the trials on RTIs, which are outcomes that seems more
likely to be affected by a relatively short duration of treatment compared with for example
CVD or cancer. The most noticeable difference between the observational and randomized tri-
als is, however, that only few of the RCTs included participants with vitamin D insufficiency.
Many studies did not report mean 25OHD levels, but among studies reporting these values,
mean levels were below 50 nmol/L in less than half of the studies and the intervention did not
result in a marked increase in 25OHD levels in several of the trials. Only a few of the included
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MAs investigated whether findings differed according to baseline vitamin D status showing no
significant interaction between results from studies with mean 25OHD levels below vs. above
50 nmol/L or according to whether supplementation resulted in increased 25OHD levels on
cardiovascular outcomes [49], blood pressure [81], body weight [137], malignant diseases
[184], RTI [212,218] or mortality [49,270,276,277]. A significant interaction term (Pi = 0.006)
was only shown for RTI in the recently published MA by Martineau et al [22] showing a larger
decrease in risk of RTI if baseline 25OHD levels are below as compared with above 25 nmol/L.
Of importance, a mean level below 50 nmol/L implies that only approximately half of the pop-
ulation had levels below 50 nmol/L, which may have blunted a potential effect in subjects with
low levels. Accordingly, it is questionable whether available trials as well as MAs performed by
combining trial results in reality have tested the hypothesis raised by observational studies on
adverse health effects of low 25OHD levels. A beneficial effect of vitamin D supplementation is
most likely difficult to demonstrate if studies are performed in populations with adequate lev-
els. Moreover, factors such as compliance, sources of vitamin D, etc. have to be considered
when evaluating findings from RCTs as well as in the design of further studies [194,282]. We
choose to classify studies according to a cut-off plasma level of 25OHD equal to 50 nmol/L, as
consensus exist on considering this threshold limit as a state of inadequacy [283], although
some have suggested that a sufficient vitamin D status requires levels above 80 nmol/L [284].
Importantly, the optimal 25OHD level for non-skeletal health outcomes have not yet been clar-
ified and the available RCTs do not allow for such definitions [27]. Lack of effects may be
attributable to use of too low doses of vitamin D to archice a sufficient response. In terms of
this, it may be of relevance in future studies also to consider the relationship between vitamin
D dose, baseline and achieved 25OHD concentrations as well as the fact that the relationship
between vitamin D dose and 25OHD concentration is nonlinear and can vary due to personal
factors [194].
A further limitation to some of the RCTs might be that some of the studies have used inter-
mitten treatment with high doses of vitamin D. Although such dosing regimes results in high
levels of 25OHD, levels of cholecalciferol are neglible for most of the time due to the rapid
25-hydroxylation of vitamin D3 into 25OHD. Vitamin D3 acts as a substrate in many tissues
thereby being of importance to the vitamin D endocrine/autocrine system. Accordingly, it is
likely that vitamin D3 should be available on a daily basis through supplementation or en-
dogenous synthesis in order to archive effects of vitamin D3 [285]. It may also be questioned
whether effects of supplementation with vitamin D are equal to endogenous synthesis. In
recent studies, novel secosteroids with potential actions similar to 25OHD have been shown to
be synthesized in vivo in human epidermis and in pig adrenal glands [286]. These compounds
may function as substrates for the 1α-hydroxylase and thereby potentially act in a manner sim-
ilarly to activated vitamin D. Further studies are needed to determine whether this is of impor-
tance to the effects of vitamin D and if it makes a difference whether vitamin D is synthesized
endogenously or provided as in terms of supplementation with cholecalciferol. Additionally,
UV irradiation through sun-exposure may also cause liberation of nitric oxide from subcuta-
neous nitrogen stores thereby affecting non-skeletal outcomes such as blood pressure beyond
potential effects of vitamin D synthesis [287–289]. Finally, it should also be noted that our
assessement of findings on non-skeletal outcomes is not exhaustive, as effects of vitamin D
supplementation also have been studied on other outcomes such as dental caries [290].
Directions for further investigations
As highlighted by our review, the quality of data from available RCTs is of limited value in
terms of assessing non-skeletal effects of vitamin D supplementation. Further MAs performed
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on these data are therefore not to be considered as a priority. MA does not compensate for
shortcomings in the original studies. Further RCTs designed to assess effects of vitamin D sup-
plementation on specific outcomes within a population at risk are warranted. A number of
large-scale trials are currently being performed. These studies aim at assessing non-skeletal
outcomes of vitamin D supplementation and first results are expected within the next year
[291,292]. Although these studies plan to include from 6,000 to 25,874 participants, and
thereby potentially provide a substantial statistical power to detect potential effects, most of
these studies are not targeted towards subjects with vitamin D insufficiency [293]. Accord-
ingly, they do not assess effects of the intervention in a population at specific risk where poten-
tial effects of improving vitamin D status may be blunted by inclusion of individuals with a
replete vitamin D status.
Assessing effects of vitamin D supplementation in randomized trials is complicated by a
number of factors [294]. Even if a large-scale study was performed in a population with vita-
min D insufficiency at baseline, changes in vitamin D status may occur in the control group
during the course of the trial due to altered dietary habits and/or sun-exposure, including sea-
sonal-variations [295–297]. Moreover, vitamin D supplements are readily available and con-
trols may start using vitamin supplements. Finally, assessment of effects in diseases which
develop over a long time span such as CVD or obesity may be difficult during the course of a
trial which most often only runs for a few years. Effects may also depend on the age of studied
subjects and risk for developing such chronic diseases may be grounded in early life [298,299].
If so, a replete vitamin D status throughout life or at certain ages may be of importance.
Although RCTs are considered to provide the highest degree of evidence on causal relation-
ships, this methodology may not be appropriate to rely on, if the effects of vitamin D are of
importance at a certain period of life or during a long time span. Thus, the importance of well-
designed longitudinal studies should not be entirely rejected. Development of new methods or
reliance on the Bradford Hill criteria may be necessary to refind our understanding of vitamin
D [300]. A major limitation to the interpretation of prior longitudinal studies is lack of stan-
dardization of 25OHD measurements [301]. It has been documented that use of different
methods for measuring 25OHD levels may cause huge variations in levels measured and
thereby affect the classification of vitamin D status [302–305]. Further observational studies
should therefore aim at using standardized methods for vitamin D measurements in order to
allow for comparisons across studies and time periods. Such observational studies may also
help to provide guidance on threshold values of 25OHD levels of importance to non-skeletal
outcomes.
Conclusions
Observational studies have suggested an inverse association between vitamin D status and a
number of diseases. Results from RCTs and MAs of RCTs do, however, only provide limited
support for such effects, as most studies have failed to document significant effects. Neverthe-
less, several MAs have suggested a reduced mortality in response to vitamin D s supplementa-
tion, as well as three of seven MAs showed a beneficial effect on RTIs, including a recently
published large individual patient data analysis [22]. Only sparse evidence are available for a
beneficial effect of supplementation on other non-skeletal outcomes such as blood pressure,
depression, and increased birth weight. No MAs based on findings from RCTs have so far
provided support for a beneficial effect of supplementation on risk of CVD, T2D, body weight,
or malignant diseases. More than half of the available trials have been performed in indivi-
duals without vitamin D insufficiency and the intervention has not resulted in an adequate
increase in 25OHD levels in many of the trials. Furthermore, the sample size in most RCTs
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was relatively small and the trials had a short duration of follow-up. In accordance with the
null findings in most RCTs, most meta-analyses have not shown effects of vitamin D supple-
mentation on non-skeletal outcoms. Importantly, as evaluated by the AMSTAR score, the
quality of published MAs has largely been fair to good. The null findings of MAs are therefore
not attributable to an inappropriate methodology when combining data from RCTs. MAs can-
not be expected to proof potential effects of supplementation with vitamin D, if the trials form-
ing the basis for the MAs have not been performed in populations with low 25OHD levels.
Overall, a definite causal link between vitamin D insufficiency and non-skeletal diseases has
not been proven, but the RCTs performed so far cannot be considered to have tested the
hypothesis raised by observational studies on adverse health outcomes of low vitamin D levels.
As a “healthy user” bias and reverse causation cannot be excluded in observational studies, fur-
ther RCTs designed to test the hypothesis of a beneficial effect of optimizing vitamin D status
in individuals with an impaired vitamin D status are warranted, as well as long-term cohort
studies using standardized methods for serial measurement of 25OHD levels.
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